"New" infectious diseases: Clinical tests on innovative Themis vaccine

A vaccine against the dreaded Chikungunya fever, developed by Vienna-based biotech company Themis Bioscience, is now undergoing clinical testing for the first time. The vaccine, which is based on a standard anti-measles vaccine, offers a genuine opportunity to halt the spread of the disease, which was originally restricted to tropical countries. Due to a lack of vaccinations, the infection is now also becoming a growing threat to industrialized countries as a result of increased foreign travel...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news